Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 27:20:821-830.
doi: 10.2147/COPD.S505855. eCollection 2025.

The Impact of Age and Disease Entity on Small Airway Dysfunction in Obstructive Airway Diseases

Affiliations

The Impact of Age and Disease Entity on Small Airway Dysfunction in Obstructive Airway Diseases

Yang Li et al. Int J Chron Obstruct Pulmon Dis. .

Abstract

Purpose: Small airway dysfunction (SAD) is prevalent in asthma and chronic obstructive pulmonary disease (COPD). Aging is acknowledged to be associated with the loss of small airway structures. However, the impact of aging and pathophysiological changes on SAD in asthma and COPD remains unclear. We aimed to investigate the impact of aging and disease entity on pathophysiological change-related SAD in asthma and COPD assessed by spirometry and impulse oscillometry (IOS).

Patients and methods: We retrospectively reviewed adult patients diagnosed with asthma or COPD between May 2017 and August 2021 in Taipei Veterans General Hospital. Treatment-naïve COPD patients aged ≥60 years were enrolled, along with age- and gender-matched elderly asthmatics (EA), and younger asthmatics aged <60 years (YA) for comparison. All participants underwent spirometry and IOS with a bronchodilator test. Blood eosinophil counts (BECs) and immunoglobulin E(IgE) levels were documented if blood tests were conducted at the time of diagnosis.

Results: The mean age of YA, EA, and COPD were 44, 73, and 73 years, respectively. The FEV1, FEV1/FVC and FEF25-75% were higher in the YA followed by EA and COPD groups. The spirometric values were significantly correlated with IOS parameters in both asthmatic and COPD groups. No significant differences were observed in baseline IOS parameters among the three groups for participants with FEV1 ≥80% predicted. However, in patients with FEV1< 80% predicted, COPD patients exhibited significantly worse spirometric values and most IOS parameters (except R5-R20) compared to asthmatics. Additionally, asthmatics with AX reduction ≥35% exhibited significantly higher levels of blood eosinophil counts and IgE.

Conclusion: Aging process contributes to more impact on small airway reactance in asthma, while disease entity in COPD exhibits worse spirometric and IOS parameters compared to the age- and gender-matched EA.

Keywords: COPD; IOS; SAD; aging; chronic obstructive pulmonary disease; elderly asthma; impulse oscillometry; small airway dysfunction.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest related to this subject matter or materials discussed in this article.

References

    1. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645–2653. doi:10.1056/NEJMoa032158 - DOI - PubMed
    1. Mauad T, Bel EH, Sterk PJ. Asthma therapy and airway remodeling. J Allergy Clin Immunol. 2007;120(5):997–1009. doi:10.1016/j.jaci.2007.06.031 - DOI - PubMed
    1. Riley CM, Wenzel SE, Castro M, et al. Clinical implications of having reduced mid forced expiratory flow rates (FEF25-75, independently of FEV1, in adult patients with asthma. PloS One. 2015;10(12):e0145476. - PMC - PubMed
    1. Postma DS, Brightling C, Baldi S, et al. Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study. Lancet Respir Med. 2019;7(5):402–416. doi:10.1016/S2213-2600(19)30049-9 - DOI - PubMed
    1. Crisafulli E, Pisi R, Aiello M, et al. Prevalence of small-airway dysfunction among COPD patients with different GOLD stages and its role in the impact of disease. Respiration. 2017;93(1):32–41. doi:10.1159/000452479 - DOI - PubMed

Publication types

Substances